Acceptability of risk stratification within population-based cancer screening from the perspective of the general public: A mixed-methods systematic review.

Lily C Taylor, Alison Hutchinson, Katie Law, Veeraj Shah, Juliet A Usher-Smith, Rebecca A Dennison
Author Information
  1. Lily C Taylor: The Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. ORCID
  2. Alison Hutchinson: School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  3. Katie Law: School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  4. Veeraj Shah: The Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  5. Juliet A Usher-Smith: The Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. ORCID
  6. Rebecca A Dennison: The Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. ORCID

Abstract

INTRODUCTION: Risk-stratified cancer screening has the potential to improve resource allocation and the balance of harms and benefits by targeting those most likely to benefit. Public acceptability has implications for engagement, uptake and the success of such a programme. Therefore, this review seeks to understand whether risk stratification of population-based cancer screening programmes is acceptable to the general public and in what context.
METHODS: Four electronic databases were searched from January 2010 to November 2021. Qualitative, quantitative and mixed-methods papers were eligible for inclusion. The Joanna Briggs Institute convergent integrated approach was used to synthesize the findings and the quality of included literature was assessed using the Mixed Methods Appraisal Tool. The Theoretical Framework of Acceptability was used as a coding frame for thematic analysis. PROSPERO record 2021 CRD42021286667.
RESULTS: The search returned 12,039 citations, 22 of which were eligible for inclusion. The majority of studies related to breast cancer screening; other cancer types included ovarian, kidney, colorectal and prostate cancer. Risk stratification was generally acceptable to the public, who considered it to be logical and of wider benefit than existing screening practices. We identified 10 priorities for implementation across four key areas: addressing public information needs; understanding communication preferences for risk estimates; mitigating barriers to accessibility to avoid exacerbating inequalities; and the role of healthcare professionals in relation to supporting reduced screening for low-risk individuals.
CONCLUSION: The public generally find risk stratification of population-based cancer screening programmes to be acceptable; however, we have identified areas that would improve implementation and require further consideration.
PATIENT OR PUBLIC CONTRIBUTION: This paper is a systematic review and did not formally involve patients or the public; however, three patient and public involvement members were consulted on the topic and scope before the review commenced.

Keywords

References

  1. BMC Cancer. 2020 Oct 6;20(1):965 [PMID: 33023516]
  2. BMJ Open. 2020 Jul 19;10(7):e034661 [PMID: 32690501]
  3. Prev Med Rep. 2021 Aug 19;24:101529 [PMID: 34976606]
  4. Psychooncology. 2019 May;28(5):1056-1062 [PMID: 30848018]
  5. BMC Cancer. 2020 Mar 24;20(1):247 [PMID: 32209062]
  6. Patient Educ Couns. 2020 Jan;103(1):83-95 [PMID: 31439435]
  7. Health Expect. 2021 Apr;24(2):341-351 [PMID: 33264472]
  8. BMC Health Serv Res. 2017 Jan 26;17(1):88 [PMID: 28126032]
  9. BMC Cancer. 2021 May 29;21(1):637 [PMID: 34051753]
  10. J Natl Cancer Inst. 2015 Feb 06;107(4): [PMID: 25663695]
  11. Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):773-780 [PMID: 33067592]
  12. Health Expect. 2021 Aug;24(4):1326-1336 [PMID: 33974726]
  13. Patient Educ Couns. 2022 Aug;105(8):2757-2762 [PMID: 35440375]
  14. Genet Med. 2019 Aug;21(8):1708-1718 [PMID: 30643217]
  15. BMC Womens Health. 2016 Jul 26;16:46 [PMID: 27460568]
  16. J Pers Med. 2021 Sep 30;11(10): [PMID: 34683136]
  17. J Public Health (Oxf). 2014 Jun;36(2):285-91 [PMID: 23986542]
  18. Public Health Genomics. 2013;16(4):184-91 [PMID: 23838408]
  19. J Pers Med. 2021 Feb 02;11(2): [PMID: 33540785]
  20. J Med Screen. 2020 Sep;27(3):138-145 [PMID: 31701797]
  21. Cancers (Basel). 2021 Aug 18;13(16): [PMID: 34439302]
  22. PLoS One. 2023 Feb 24;18(2):e0279201 [PMID: 36827432]
  23. PLoS One. 2022 Jan 13;17(1):e0262197 [PMID: 35025940]
  24. Fam Cancer. 2015 Mar;14(1):135-44 [PMID: 25391615]
  25. JMIR Cancer. 2019 Apr 11;5(1):e12307 [PMID: 30973340]
  26. Cancer Prev Res (Phila). 2019 Jun;12(6):383-390 [PMID: 31003994]
  27. Health Expect. 2023 Jun;26(3):989-1008 [PMID: 36852880]
  28. BMJ Open. 2018 Jul 18;8(7):e021782 [PMID: 30021754]
  29. JAMA Netw Open. 2018 Dec 7;1(8):e185461 [PMID: 30646275]
  30. JBI Evid Synth. 2020 Oct;18(10):2108-2118 [PMID: 32813460]
  31. Cancer Control. 2022 Jan-Dec;29:10732748211060289 [PMID: 34986038]
  32. Cancers (Basel). 2021 Nov 19;13(22): [PMID: 34830965]
  33. Acta Oncol. 2018 Oct;57(10):1275-1283 [PMID: 29882455]
  34. Health Expect. 2022 Aug;25(4):1789-1806 [PMID: 35526275]
  35. Chin J Cancer Res. 2019 Apr;31(2):316-328 [PMID: 31156302]
  36. Cancer Prev Res (Phila). 2016 Jan;9(1):13-26 [PMID: 26464100]
  37. Int J Cancer. 2022 Feb 1;150(3):397-405 [PMID: 34460107]
  38. Acta Oncol. 2016;55(1):45-51 [PMID: 25990635]
  39. Public Health Res Pract. 2019 Jul 31;29(2): [PMID: 31384886]
  40. J Med Screen. 2020 Mar;27(1):52-56 [PMID: 31575328]
  41. BMC Cancer. 2020 May 20;20(1):452 [PMID: 32434564]
  42. Public Health Genomics. 2011;14(4-5):238-47 [PMID: 20090298]
  43. Breast. 2015 Jun;24(3):237-41 [PMID: 25708717]
  44. BJU Int. 2022 Nov;130(5):550-561 [PMID: 35460182]
  45. J Health Commun. 2004 Jan-Feb;9(1):53-65 [PMID: 14761833]
  46. J Gen Intern Med. 2018 Nov;33(11):1905-1912 [PMID: 30066118]
  47. Br J Health Psychol. 2018 Sep;23(3):519-531 [PMID: 29453791]

MeSH Term

Male
Humans
Early Detection of Cancer
Qualitative Research
Communication
Health Personnel
Risk Assessment
Neoplasms

Word Cloud

Created with Highcharts 10.0.0cancerscreeningpublicreviewriskstratificationpopulation-basedacceptablesystematicimprovebenefitacceptabilityprogrammesgeneral2021mixed-methodseligibleinclusionusedincludedAcceptabilitygenerallyidentifiedimplementationhoweverINTRODUCTION:Risk-stratifiedpotentialresourceallocationbalanceharmsbenefitstargetinglikelyPublicimplicationsengagementuptakesuccessprogrammeThereforeseeksunderstandwhethercontextMETHODS:FourelectronicdatabasessearchedJanuary2010NovemberQualitativequantitativepapersJoannaBriggsInstituteconvergentintegratedapproachsynthesizefindingsqualityliteratureassessedusingMixedMethodsAppraisalToolTheoreticalFrameworkcodingframethematicanalysisPROSPEROrecordCRD42021286667RESULTS:searchreturned12039citations22majoritystudiesrelatedbreasttypesovariankidneycolorectalprostateRiskconsideredlogicalwiderexistingpractices10prioritiesacrossfourkeyareas:addressinginformationneedsunderstandingcommunicationpreferencesestimatesmitigatingbarriersaccessibilityavoidexacerbatinginequalitiesrolehealthcareprofessionalsrelationsupportingreducedlow-riskindividualsCONCLUSION:findareasrequireconsiderationPATIENTORPUBLICCONTRIBUTION:paperformallyinvolvepatientsthreepatientinvolvementmembersconsultedtopicscopecommencedwithinperspectivepublic:mixedmethods

Similar Articles

Cited By